| Q35647162 | A fluorescent approach for identifying P2X1 ligands |
| Q35025905 | A three-stage biophysical screening cascade for fragment-based drug discovery. |
| Q30387229 | Advances in Nuclear Magnetic Resonance for Drug Discovery |
| Q34616682 | Advances in fragment-based drug discovery platforms |
| Q34019272 | Application of NMR and molecular docking in structure-based drug discovery |
| Q30411815 | Application of fragment-based drug discovery to membrane proteins: identification of ligands of the integral membrane enzyme DsbB |
| Q26779035 | Charting a Path to Success in Virtual Screening |
| Q35532349 | Composing compound libraries for hit discovery--rationality-driven preselection or random choice by structural diversity? |
| Q24633082 | Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor |
| Q34614630 | Cytotoxic activity and apoptosis-inducing potential of di-spiropyrrolidino and di-spiropyrrolizidino oxindole andrographolide derivatives |
| Q33730340 | Design of Screening Collections for Successful Fragment-Based Lead Discovery |
| Q33440704 | Development and NMR validation of minimal pharmacophore hypotheses for the generation of fragment libraries enriched in heparanase inhibitors |
| Q57773818 | Discovery of Inhibitors of Protein-Protein Interactions Using Fragment-Based Methods |
| Q38028520 | Discovery of novel antibacterials |
| Q28246329 | Discovery of plasmepsin inhibitors by fragment-based docking and consensus scoring |
| Q33702000 | Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules |
| Q55284202 | Evaluating novel synthetic compounds active against Bacillus subtilis and Bacillus cereus spores using Live imaging with SporeTrackerX. |
| Q90257936 | Extending the Detection Limit in Fragment Screening of Proteins Using Reverse Micelle Encapsulation |
| Q28833921 | Fragment Screening of Human Aquaporin 1 |
| Q37995087 | Fragment informatics and computational fragment-based drug design: an overview and update |
| Q33969281 | Fragment library screening reveals remarkable similarities between the G protein-coupled receptor histamine H₄ and the ion channel serotonin 5-HT₃A. |
| Q58409867 | Fragment screening against the thiamine pyrophosphate riboswitchthiM |
| Q26826945 | Fragment screening and HIV therapeutics |
| Q39043214 | Fragment screening and druggability assessment for the CBP/p300 KIX domain through protein-observed 19F NMR spectroscopy |
| Q42882505 | Fragment-Based Screening by Biochemical Assays: Systematic Feasibility Studies with Trypsin and MMP12 |
| Q36382655 | Fragment-based drug discovery as alternative strategy to the drug development for neglected diseases. |
| Q39731911 | Fragment-based lead discovery: challenges and opportunities |
| Q27660547 | Fragment-based lead discovery: screening and optimizing fragments for thermolysin inhibition |
| Q38029118 | In silico fragment-based drug design |
| Q55333010 | Insight into small molecule binding to the neonatal Fc receptor by X-ray crystallography and 100 kHz magic-angle-spinning NMR. |
| Q36385771 | Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5. |
| Q92258025 | Interrogating the Essential Bacterial Cell Division Protein FtsQ with Fragments Using Target Immobilized NMR Screening (TINS) |
| Q57230716 | MS methods to study macromolecule-ligand interaction: Applications in drug discovery |
| Q48166476 | NMR-Fragment Based Virtual Screening: A Brief Overview |
| Q27679837 | Non-peptidic cruzain inhibitors with trypanocidal activity discovered by virtual screening and in vitro assay |
| Q27665277 | Novel insights for dihydroorotate dehydrogenase class 1A inhibitors discovery |
| Q35741775 | One Question, Multiple Answers: Biochemical and Biophysical Screening Methods Retrieve Deviating Fragment Hit Lists |
| Q33509963 | Practical aspects of the SAMPL challenge: providing an extensive experimental data set for the modeling community |
| Q51642295 | Protein-observed (19)F-NMR for fragment screening, affinity quantification and druggability assessment. |
| Q33893113 | Recent trends and observations in the design of high-quality screening collections |
| Q84366158 | Small molecule binding to proteins: affinity and binding/unbinding dynamics from atomistic simulations |
| Q35738960 | State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors |
| Q48328418 | Synthesis and antiproliferative and apoptosis-inducing activity of novel 3-substituted-3-hydroxy-2-oxindole compounds. |
| Q39446193 | Synthesis and biological evaluation of 3-substituted-indolin-2-one derivatives containing chloropyrrole moieties. |
| Q33684605 | Target Immobilization as a Strategy for NMR-Based Fragment Screening: Comparison of TINS, STD, and SPR for Fragment Hit Identification |
| Q33896509 | Targeting metalloproteins by fragment-based lead discovery |
| Q33779423 | The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches |
| Q33789461 | The importance of discerning shape in molecular pharmacology |
| Q33469695 | The multiple roles of computational chemistry in fragment-based drug design |
| Q33913583 | Visualisation of the chemical space of fragments, lead-like and drug-like molecules in PubChem |